Low incidence of lymphoproliferative disease post kidney transplantation with prevalent use of alemtuzumab
Introduction: It is well known that the incidence of malignancy is significantly higher in transplanted patients than in general population. The incidence of lymphoproliferative disease post-transplantation (PTLD) is approximately of 1% to 2% in kidney transplantation recipients. Objective: The main...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Asociación Regional de Diálisis y Trasplantes Renales de Capital Federal y Provincia de Buenos Aires
2014-01-01
|
| Series: | Revista de Nefrología, Diálisis y Trasplante |
| Subjects: | |
| Online Access: | http://www.revistarenal.org.ar/index.php/rndt/article/view/99 |
| _version_ | 1818322793983377408 |
|---|---|
| author | John Fredy Nieto-Ríos Arbey Aristizabal-Alzate Catalina Ocampo-Kohn Juan José Vanegas-Ruiz Catalina Vélez-Echeverri Lina María Serna-Higuita Daniel Camilo Aguirre Carlos Enrique Yepes-Delgado Gustavo Zuluaga-Valencia |
| author_facet | John Fredy Nieto-Ríos Arbey Aristizabal-Alzate Catalina Ocampo-Kohn Juan José Vanegas-Ruiz Catalina Vélez-Echeverri Lina María Serna-Higuita Daniel Camilo Aguirre Carlos Enrique Yepes-Delgado Gustavo Zuluaga-Valencia |
| author_sort | John Fredy Nieto-Ríos |
| collection | DOAJ |
| description | Introduction: It is well known that the incidence of malignancy is significantly higher in transplanted patients than in general population. The incidence of lymphoproliferative disease post-transplantation (PTLD) is approximately of 1% to 2% in kidney transplantation recipients. Objective: The main objective of this study was to evaluate the PTLD incidence when monitoring kidney transplanted patients between the years 2005 and 2010. Methods: Kidney transplanted patients’ data was retrospectively taken between the years 2005 to 2010 in order to determine the number of PTLD cases according to the inductor scheme used. Results: 425 patients were transplanted between 2005 and 2010. They received alemtuzumab 76.2%, daclizumab 10.7%, basiliximab 3.6% and thymoglobulin 2.4%. The 7% did not receive antibody induction. During this period 2 cases of PTLD ocurred: One with multiple myeloma and the other with lymphoma. One of them had been treated with alemtuzumab and the other with thymoglobulin. Conclusions: The PTLD incidence in our group, where alemtuzumab was used predominantly as inductor, was very low; this might suggest that alemtuzumab is a medication that does not increase the risk of this kind of neoplasia. |
| first_indexed | 2024-12-13T11:02:27Z |
| format | Article |
| id | doaj.art-13772576f35c4813be9753f0f6e1db01 |
| institution | Directory Open Access Journal |
| issn | 0326-3428 2346-8548 |
| language | Spanish |
| last_indexed | 2024-12-13T11:02:27Z |
| publishDate | 2014-01-01 |
| publisher | Asociación Regional de Diálisis y Trasplantes Renales de Capital Federal y Provincia de Buenos Aires |
| record_format | Article |
| series | Revista de Nefrología, Diálisis y Trasplante |
| spelling | doaj.art-13772576f35c4813be9753f0f6e1db012022-12-21T23:49:13ZspaAsociación Regional de Diálisis y Trasplantes Renales de Capital Federal y Provincia de Buenos AiresRevista de Nefrología, Diálisis y Trasplante0326-34282346-85482014-01-01341212699Low incidence of lymphoproliferative disease post kidney transplantation with prevalent use of alemtuzumabJohn Fredy Nieto-Ríos0Arbey Aristizabal-Alzate1Catalina Ocampo-Kohn2Juan José Vanegas-Ruiz3Catalina Vélez-Echeverri4Lina María Serna-Higuita5Daniel Camilo Aguirre6Carlos Enrique Yepes-Delgado7Gustavo Zuluaga-Valencia8Sección Nefrología y Trasplante Renal, Hospital Pablo Tobón Uribe, MedellínSección Nefrología y Trasplante Renal, Hospital Pablo Tobón Uribe, MedellínSección Nefrología y Trasplante Renal, Hospital Pablo Tobón Uribe, MedellínSección Nefrología y Trasplante Renal, Hospital Pablo Tobón Uribe, MedellínSección Nefrología y Trasplante Renal, Hospital Pablo Tobón Uribe, MedellínSección Nefrología y Trasplante Renal, Hospital Pablo Tobón Uribe, MedellínInstituto de Investigaciones Médicas, Universidad de Antioquia, AntioquíaSección de investigación, Hospital Pablo Tobón Uribe, MedellínSección Nefrología y Trasplante Renal, Hospital Pablo Tobón Uribe, MedellínIntroduction: It is well known that the incidence of malignancy is significantly higher in transplanted patients than in general population. The incidence of lymphoproliferative disease post-transplantation (PTLD) is approximately of 1% to 2% in kidney transplantation recipients. Objective: The main objective of this study was to evaluate the PTLD incidence when monitoring kidney transplanted patients between the years 2005 and 2010. Methods: Kidney transplanted patients’ data was retrospectively taken between the years 2005 to 2010 in order to determine the number of PTLD cases according to the inductor scheme used. Results: 425 patients were transplanted between 2005 and 2010. They received alemtuzumab 76.2%, daclizumab 10.7%, basiliximab 3.6% and thymoglobulin 2.4%. The 7% did not receive antibody induction. During this period 2 cases of PTLD ocurred: One with multiple myeloma and the other with lymphoma. One of them had been treated with alemtuzumab and the other with thymoglobulin. Conclusions: The PTLD incidence in our group, where alemtuzumab was used predominantly as inductor, was very low; this might suggest that alemtuzumab is a medication that does not increase the risk of this kind of neoplasia.http://www.revistarenal.org.ar/index.php/rndt/article/view/99enfermedad linfoproliferativa post trasplantePTLDtrasplante renalalemtuzumab |
| spellingShingle | John Fredy Nieto-Ríos Arbey Aristizabal-Alzate Catalina Ocampo-Kohn Juan José Vanegas-Ruiz Catalina Vélez-Echeverri Lina María Serna-Higuita Daniel Camilo Aguirre Carlos Enrique Yepes-Delgado Gustavo Zuluaga-Valencia Low incidence of lymphoproliferative disease post kidney transplantation with prevalent use of alemtuzumab Revista de Nefrología, Diálisis y Trasplante enfermedad linfoproliferativa post trasplante PTLD trasplante renal alemtuzumab |
| title | Low incidence of lymphoproliferative disease post kidney transplantation with prevalent use of alemtuzumab |
| title_full | Low incidence of lymphoproliferative disease post kidney transplantation with prevalent use of alemtuzumab |
| title_fullStr | Low incidence of lymphoproliferative disease post kidney transplantation with prevalent use of alemtuzumab |
| title_full_unstemmed | Low incidence of lymphoproliferative disease post kidney transplantation with prevalent use of alemtuzumab |
| title_short | Low incidence of lymphoproliferative disease post kidney transplantation with prevalent use of alemtuzumab |
| title_sort | low incidence of lymphoproliferative disease post kidney transplantation with prevalent use of alemtuzumab |
| topic | enfermedad linfoproliferativa post trasplante PTLD trasplante renal alemtuzumab |
| url | http://www.revistarenal.org.ar/index.php/rndt/article/view/99 |
| work_keys_str_mv | AT johnfredynietorios lowincidenceoflymphoproliferativediseasepostkidneytransplantationwithprevalentuseofalemtuzumab AT arbeyaristizabalalzate lowincidenceoflymphoproliferativediseasepostkidneytransplantationwithprevalentuseofalemtuzumab AT catalinaocampokohn lowincidenceoflymphoproliferativediseasepostkidneytransplantationwithprevalentuseofalemtuzumab AT juanjosevanegasruiz lowincidenceoflymphoproliferativediseasepostkidneytransplantationwithprevalentuseofalemtuzumab AT catalinavelezecheverri lowincidenceoflymphoproliferativediseasepostkidneytransplantationwithprevalentuseofalemtuzumab AT linamariasernahiguita lowincidenceoflymphoproliferativediseasepostkidneytransplantationwithprevalentuseofalemtuzumab AT danielcamiloaguirre lowincidenceoflymphoproliferativediseasepostkidneytransplantationwithprevalentuseofalemtuzumab AT carlosenriqueyepesdelgado lowincidenceoflymphoproliferativediseasepostkidneytransplantationwithprevalentuseofalemtuzumab AT gustavozuluagavalencia lowincidenceoflymphoproliferativediseasepostkidneytransplantationwithprevalentuseofalemtuzumab |